Evolving Treatment in Newly Diagnosed Multiple Myeloma Patients - Episode 4
Optimizing Regimens and Managing Adverse Events in TIE NDMM
Elizabeth O’Donnell, MD, comments on specific patient subgroups, such as frail or high-risk individuals, who benefit most from particular regimens. She discusses adverse events observed in combination therapies for transplant-ineligible patients with newly diagnosed multiple myeloma and shares her approaches to managing these adverse effects in clinical practice.
- Please comment on whether there are specific patient subgroups (eg, frail or high risk) that benefit most from one regimen over the other?
- Please comment on some adverse events observed in combination therapies in transplant-ineligible patients with newly diagnosed multiple myeloma.
- Please address how you manage these adverse effects in clinical practice.
Related Content:
